The search for new anticoagulants: Dabigatran etexilate

Therapy

Volumn 5, Issue 6, 2008, Pages 793-796

  Siddique, Aurangzeb ^a   Shantsila, Eduard ^a   Lip, Gregory Y H ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBIN; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; EDITORIAL; HEART ATRIUM FIBRILLATION; HUMAN; KNEE ARTHROPLASTY; LIVER INJURY; LIVER TOXICITY; REBOUND; RISK FACTOR; SIDE EFFECT; THROMBOSIS; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM;

EID: 69449083888     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.5.6.793     Document Type: Editorial

References (16)

1. Di Nisio M, Middeldorp S, Buller HR: Direct thrombin inhibitors. N. Engl. J. Med. 10, 1028-1040 (2005).
2. Hirsh J, O'Donnell M, Eikelboom JW: Beyond unfractionated heparin and warfarin:current and future advances. Circulation 116, 552-560 (2007).
3. Weitz JI, Leslie B, Hudoba M: Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 97, 544-552 (1998).
4. Boos CJ, Lip GYH: Ximelagatran for stroke prevention in atrial fibrillation. Expert Rev. Cardiovasc. Ther. 3, 551-563 (2005).
5. Testa L, Andreotti F, Biondi Zoccai GG, Burzotta F, Bellocci F, Crea F: Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22,639 patients. Int. J. Cardiol. 122, 117-124 (2007).
6. Agnelli G, Eriksson BI, Cohen AT et al.: on behalf of the EXTEND Study Group: Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res. (2008) (Epub ahead of print).
7. Boudes PF: The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee. Contemp. Clin. Trials 27, 432-440 (2006).
8. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W: Structure-based design of novel potent nonpeptide thrombin inhibitors. J. Med. Chem. 45, 1757-1766 (2002).
9. Stangier J, Rathgen K, Staehle H, Gansser D, Roth W: The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy mate subjects. Br. J. Clin. Pharmacol. 64, 292-303 (2007).
10. Eriksson BI, Dahl OE, Ahnfelt L et al.: Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.J. Thromb. Haemost. 2, 1573-1580 (2004).
11. Eriksson BI, Dahl OE, Bueller HR et al.: A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J. Thromb. Haemost. 3, 103-111 (2005).
12. Eriksson BI, Dahl OE, van Dijk CN et al.: A new oral anticoagulant, dabigatran etexilate, is effective and safe in preventing venous thromboembolism after total knee replacement surgery. Blood 108, 11 (2006).
13. Eriksson BI, Dahl OE, Rosencher N et al.; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370, 949-956 (2007).
14. The RE-MOBILIZE Writing Committee: The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J. Arthroplasty DOI: 10.1016/j.arth.2008.01-132 (2008) (Epub ahead of print).
15. Ezekowitz MD, Reilly PA, Nehmiz G et al.: Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am. J. Cardiol. 100 (9), 1419-1426 (2007).
16. Ieko M, Tarumi T, Takeda M, Naito S, Nikabayashi T, Koike T: Synthetic selective inhibitors of coagulation factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis. J. Thromb. Haemost. 2, 612-618 (2004).